Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: A multicenter phase 2 trial (AGO-GYN5)
Günter Emons*, Grigor Gorchev, Philipp Harter, Pauline Wimberger, Anne Stähle, Lars Hanker, Felix Hilpert, Matthias W. Beckmann, Peter Dall, Carsten Gründker, Herbert Sindermann, Jalid Sehouli
Untersuchen Sie die Forschungsthemen von „Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: A multicenter phase 2 trial (AGO-GYN5)“. Zusammen bilden sie einen einzigartigen Fingerprint.